35
Views
2
CrossRef citations to date
0
Altmetric
Letter

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

, , &
Pages 353-356 | Published online: 18 Jan 2016

References

  • WoollardSMKanmogneGDMaraviroc: a review of its use in HIV infection and beyondDrug Des Devel Ther2015954475468
  • GenebatMRuiz-MateosELeonJACorrelation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patientsJ Antimicrob Chemother20096484584919671585
  • Gonzalez-SernaAMcGovernRAHarriganPRCorrelation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methodsAntimicrob Agents Chemother2012561202120722143533
  • Hernández-NovoaBMadrid-ElenaNDrondaFVirological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patientsJ Antimicrob Chemother2014691916191924623833
  • Gonzalez-SernaALealMGenebatMTROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approachesJ Clin Microbiol2010484453445820943871
  • GenebatMRuiz-MateosEGonzález-SernaADiscordance rates between Trofile test and short-term virological response to maravirocAntiviral Res20118918218521134404
  • GenebatMde Pablo-BernalRSPulidoIMaraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patientsAntiviral Res2015121949626122170
  • MoyleGJWildfireAMandaliaSEpidemiology and predictive factors for chemokine receptor use in HIV-1 infectionJ Infect Dis200519186687215717260

References

  • WoollardSMKanmogneGDMaraviroc: a review of its use in HIV infection and beyondDrug Des Devel Ther2015954475468
  • Hernández-NovoaBMadrid-ElenaNDrondaFVirological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patientsJ Antimicrob Chemother20146971916191924623833
  • WestbyMLewisMWhitcombJEmergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoirJ Virol200680104909492016641282
  • BaatzFStruckDLemaireMRescue of HIV-1 long-time archived X4 strains to escape maravirocAntiviral Res201192348849222020304
  • Recordon-PinsonPRaymondSBellecavePHIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replicationAntimicrob Agents Chemother201357293093523208718
  • SwensonLCChuiCKBrummeCJGenotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failureAntimicrob Agents Chemother201357126122613024080655
  • DelobelPSandres-SauneKCazabatMR5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapyJ Acquir Immune Defic Syndr200538438239215764954
  • MooreJPKitchenSGPugachPZackJAThe CCR5 and CXCR4 coreceptors – central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infectionAIDS Res Hum Retroviruses200420111112615000703
  • GenebatMde Pablo-BernalRSPulidoIMaraviroc clinical test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naive HIV-infected patientsAntiviral Res2015121949626122170
  • GenebatMRuiz-MateosELeonJACorrelation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patientsJ Antimicrob Chemother200964484584919671585
  • ArcherJBravermanMSTaillonBEDetection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencingAIDS200923101209121819424056
  • NankyaILTebitDMAbrahaADefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageAIDS Res Ther2015123426435727
  • GenebatMRuiz-MateosEPulidoILong-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practiceCurr HIV Res20108648248620642436
  • GenebatMRuiz-MateosEGonzalez-SernaADiscordance rates between Trofile test and short-term virological response to maravirocAntiviral Res201189218218521134404
  • GenebatMPulidoIRomero-SanchezMCPatients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairmentAntiviral Res201295320721122750308
  • Gonzalez-SernaAMcGovernRAHarriganPRCorrelation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methodsAntimicrob Agents Chemother20125631202120722143533
  • Gonzalez-SernaARomero-SanchezMCFerrando-MartinezSHIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patientsAntimicrob Agents Chemother20125673981398322547624